Retinitis Pigmentosa Clinical Trials

Find Retinitis Pigmentosa Clinical Trials Near You

A Single-arm, Open-label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with RP caused by RHO site-specific gene mutation (RHO-RP). This is a single-arm, open-label, single ascending dose study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 1\. Patients with clinical diagnosis of Retinitis Pigmentosa (RP) (age ≥ 18 years) ;

• 2\. Genetic test confirmed to carry a fix mutation of RHO and carry no pathogenic mutations of other ophthalmic genetic diseases;

• 3\. Meet the following target eye selection criteria: Best corrected visual acuity between 2.3 LogMAR and 0.5 LogMAR (including 2.3 LogMAR and 0.5 LogMAR, equivalent to Snellen visual acuity of hand move to 20/63) ;

• 4\. Agree to take effective contraceptive measures from the beginning of the study to 1 year after the administration;

• 5.Willingness to adhere to protocol as evidenced by written informed consent;

⁃ Definition of the study eye: The study eye is defined as the eye with worse visual acuity between the two eyes of each prospective subject. For all subjects, only one eye shall be designated as the study eye (i.e., the eye receiving treatment). If both eyes of a patient meet the eligibility criteria and have equal visual acuity, the investigator shall determine the study eye based on clinical judgment.

Locations
Other Locations
China
Peking University Third Hospital
RECRUITING
Beijing
Contact Information
Primary
Liping Yang, MD
alexlipingyang@bjmu.edu.cn
010-82266595
Backup
Jinlu Zhang, MD
zhangjinlu@bjmu.edu.cn
15810570898
Time Frame
Start Date: 2023-09-12
Estimated Completion Date: 2028-12
Participants
Target number of participants: 9
Treatments
Experimental: Dose escalation
Three cohorts of 3 patients each. All the patients enrolled in the study will receive a single subretinal injection in one eye.~Cohort 1: Subretinal administration of a single low dose ZVS203e at Day 0. Cohort 2: Subretinal administration of a single medium dose ZVS203e at Day 0. Cohort 3: Subretinal administration of a single high dose ZVS203e at Day 0.
Sponsors
Leads: Peking University Third Hospital

This content was sourced from clinicaltrials.gov